Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Ascendis Pharma A/S ADR (NASDAQ: ASND) closed at $200.5 in the last session, down -0.82% from day before closing price of $202.16. In other words, the price has decreased by -$0.82 from its previous closing price. On the day, 0.51 million shares were traded. ASND stock price reached its highest trading level at $204.5 during the session, while it also had its lowest trading level at $198.33.
Ratios:
We take a closer look at ASND’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.73 and its Current Ratio is at 1.03.
Upgrades & Downgrades
In the most recent recommendation for this company, Wolfe Research on November 18, 2025, initiated with a Peer Perform rating and assigned the stock a target price of $255.
On October 17, 2025, Raymond James started tracking the stock assigning a Strong Buy rating and target price of $271.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 02 ’25 when Jan Moller Mikkelsen bought 100,000 shares for $210.85 per share.
SPROGOE KENNETT bought 10,000 shares of ASND for $2,093,222 on Dec 02 ’25. On Dec 02 ’25, another insider, JENSEN FLEMMING STEEN, who serves as the Officer of the company, bought 10,000 shares for $205.85 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ASND now has a Market Capitalization of 12250180608 and an Enterprise Value of 12524738560. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.00. Its current Enterprise Value per Revenue stands at 19.372 whereas that against EBITDA is -93.672.
Stock Price History:
The Beta on a monthly basis for ASND is 0.46, which has changed by 0.5307034 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, ASND has reached a high of $223.18, while it has fallen to a 52-week low of $118.03. The 50-Day Moving Average of the stock is -2.02%, while the 200-Day Moving Average is calculated to be 11.98%.
Shares Statistics:
According to the various share statistics, ASND traded on average about 479.08K shares per day over the past 3-months and 544490 shares per day over the past 10 days. A total of 61.10M shares are outstanding, with a floating share count of 60.47M. Insiders hold about 1.03% of the company’s shares, while institutions hold 104.71% stake in the company. Shares short for ASND as of 1763078400 were 2987645 with a Short Ratio of 6.24, compared to 1760486400 on 3422190. Therefore, it implies a Short% of Shares Outstanding of 2987645 and a Short% of Float of 5.87.
Earnings Estimates
The market rating for Ascendis Pharma A/S ADR (ASND) is a result of the insights provided by 12.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.39, with high estimates of $0.83 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$2.93 and -$5.83 for the fiscal current year, implying an average EPS of -$3.38. EPS for the following year is $3.18, with 13.0 analysts recommending between $6.08 and $1.23.
Revenue Estimates
According to 10 analysts,. The current quarter’s revenue is expected to be $246.16M. It ranges from a high estimate of $255.8M to a low estimate of $225.58M. As of. The current estimate, Ascendis Pharma A/S ADR’s year-ago sales were $173.92MFor the next quarter, 10 analysts are estimating revenue of $282.79M. There is a high estimate of $331.8M for the next quarter, whereas the lowest estimate is $239.04M.
A total of 12 analysts have provided revenue estimates for ASND’s current fiscal year. The highest revenue estimate was $728.5M, while the lowest revenue estimate was $682.5M, resulting in an average revenue estimate of $714.99M. In the same quarter a year ago, actual revenue was $363.64MBased on 12 analysts’ estimates, the company’s revenue will be $1.3B in the next fiscal year. The high estimate is $1.6B and the low estimate is $1.11B.
